Ben Alencherry1, Dennis Bruemmer2,3. 1. Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA. 2. Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA. bruemmd@ccf.org. 3. Center for Cardiometabolic Health, Section of Preventive Cardiology and Rehabilitation, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue JB-815, Cleveland, OH, 44195, USA. bruemmd@ccf.org.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to provide an overview of the current quality of diabetes care in the USA, discuss barriers to guideline-recommended treatment adherence, and outline strategies for the improvement in care. RECENT FINDINGS: Current treatment guidelines highlight the importance of glycemic control, use of novel medications with proven cardiovascular efficacy, and multifactorial cardiovascular risk factor intervention for the treatment of diabetes and associated complications. Albeit proven evidence for these guidelines, the vast majority of patients with diabetes remain insufficiently treated. Interventions to improve outcomes require focus on care delivery systems, physician behavior, and patient-centered approaches. De-fragmenting care systems to form collaborative, multi-specialty teams, use of standardized and comprehensive treatment algorithms, development of quality assessment tools, avoiding physician therapeutic inertia, and addressing patient barriers, including lack of perceived benefit, insufficient diabetes education and access to care, and medication costs, represent key objectives to improve diabetes care and outcomes. Clinical research in standardized trials has proven the feasibility to reduce morbidity and mortality associated with diabetes. Implementing models of care to disseminate these encouraging research findings to the wider population and to overcome barriers to achieving guideline-recommended treatment goals should be the objective to improve our current quality of diabetes care in the USA.
PURPOSE OF REVIEW: The purpose of this review is to provide an overview of the current quality of diabetes care in the USA, discuss barriers to guideline-recommended treatment adherence, and outline strategies for the improvement in care. RECENT FINDINGS: Current treatment guidelines highlight the importance of glycemic control, use of novel medications with proven cardiovascular efficacy, and multifactorial cardiovascular risk factor intervention for the treatment of diabetes and associated complications. Albeit proven evidence for these guidelines, the vast majority of patients with diabetes remain insufficiently treated. Interventions to improve outcomes require focus on care delivery systems, physician behavior, and patient-centered approaches. De-fragmenting care systems to form collaborative, multi-specialty teams, use of standardized and comprehensive treatment algorithms, development of quality assessment tools, avoiding physician therapeutic inertia, and addressing patient barriers, including lack of perceived benefit, insufficient diabetes education and access to care, and medication costs, represent key objectives to improve diabetes care and outcomes. Clinical research in standardized trials has proven the feasibility to reduce morbidity and mortality associated with diabetes. Implementing models of care to disseminate these encouraging research findings to the wider population and to overcome barriers to achieving guideline-recommended treatment goals should be the objective to improve our current quality of diabetes care in the USA.
Entities:
Keywords:
Cardiovascular; Diabetes; Quality of care
Authors: Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245
Authors: Jose Miguel Baena-Díez; Judit Peñafiel; Isaac Subirana; Rafel Ramos; Roberto Elosua; Alejandro Marín-Ibañez; María Jesús Guembe; Fernando Rigo; María José Tormo-Díaz; Conchi Moreno-Iribas; Joan Josep Cabré; Antonio Segura; Manel García-Lareo; Agustín Gómez de la Cámara; José Lapetra; Miquel Quesada; Jaume Marrugat; Maria José Medrano; Jesús Berjón; Guiem Frontera; Diana Gavrila; Aurelio Barricarte; Josep Basora; Jose María García; Natalia C Pavone; David Lora-Pablos; Eduardo Mayoral; Josep Franch; Manel Mata; Conxa Castell; Albert Frances; María Grau Journal: Diabetes Care Date: 2016-08-04 Impact factor: 19.112
Authors: Joshua M Stolker; Dazhong Sun; Darcy G Conaway; Philip G Jones; Frederick A Masoudi; Pamela N Peterson; Harlan M Krumholz; Mikhail Kosiborod; John A Spertus Journal: Am J Cardiol Date: 2010-02-20 Impact factor: 2.778
Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez Journal: Endocr Pract Date: 2017-01-17 Impact factor: 3.443
Authors: Joshua M Stolker; John A Spertus; Darren K McGuire; Marcus Lind; Fengming Tang; Philip G Jones; Silvio E Inzucchi; Saif S Rathore; Thomas M Maddox; Frederick A Masoudi; Mikhail Kosiborod Journal: Diabetes Care Date: 2012-03-12 Impact factor: 19.112